Maintain EMR at benchmark weight; do not add at $155.10 given 33.9x P/E stretch and unresolved macro headwinds
The convergent analyst debate resolves on Hold. The Aggressive analyst wins on franchise description (26.9% operating margins, 67-year dividend Aristocrat, $2.67B TTT FCF, 710 bps gross margin expansion post-NI, fresh bullish MACD crossover 9/22) but overreaches on entry timing—the forward EPS $7.27 forecast requires multiple dependencies with 50-60% historical disappointment probability. The Conservative analyst wins on valuation stretch and macro headwinds but underweights structural defenses (rising 200 SMA, sub-2x net debt/EBITDA, 3x dividend coverage from FCF). The R/R at $155.10 with $148.30 stop is approximately 1:1 (+5.5-6% upside vs -4.4% downside), and on a beta-adjusted basis (1.23) is negative in a hawkish-Fed regime. Three failed attempts at $159.39 establishes real overhead supply. Current setup mirrors the 9/24 Hold analog (+0.8% alpha) more closely than the 9/28 stretched analog (-1.2% alpha).
| Position | Action |
|---|---|
| Current setup | Maintain benchmark weight (2-3% target) |
EMR is a best-in-class industrial compounder pivoting into software-defined automation, trading 4% off its highs with a reset, neutral-bullish technical setup, supported by a 9.3% revenue CAGR, 26.9% operating margins, $2.67B FCF, a 67-year dividend Aristocrat track record, and 55% expected EPS recovery over the next 12 months.
| Indicator | Value | Signal |
|---|---|---|
| Close | 155.10 | neutral |
| 10 EMA | 154.94 | bullish |
| 50 SMA | 153.76 | bullish |
| 200 SMA | 143.58 | bullish |
| Bollinger Middle Band (20 SMA) | 152.01 | neutral |
| Bollinger Upper Band | 159.83 | neutral |
| Bollinger Lower Band | 144.19 | neutral |
| RSI (14) | 53.35 | neutral |
| MACD Line | 1.14 | bullish |
| MACD Signal | 0.33 | bullish |
| MACD Histogram |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
EMR has best-in-class margin profile and durable competitive moat
↩ rebuts: “Bear claims premium valuation is not justified”
EV: +9.7% · concedes: Moderate position sizing warranted due to beta 1.23 and macro uncertainty; Net debt tripled to $11.6B post-NI acquisition — balance sheet flexibility is being tested; Premium valuation at 21.8x forward P/E requires flawless EPS execution; No social media presence may indicate lack of near-term re-rating catalyst
EMR is priced for a flawless execution scenario that ignores the accumulation of macro headwinds, leverage trajectory, goodwill impairment risk, and contested competitive positioning—creating a risk/reward skewed against long positions at $155.10.
· concedes: EMR is a quality franchise with real margin durability and a real software-mix tailwind; The 67-year dividend track record reflects genuine business quality; Operating income did jump from $2.36B (FY22) to $3.53B (FY25); The committed capex backlog (e.g., $20B semiconductor fab) won't get cancelled when 10Y moves 50bps; A confirmed multi-quarter EPS delivery at or above $7.27 with no goodwill impairment and stable margins would prove the bull's thesis; The market will eventually deliver a better entry
→ vs conservative: Anchoring on trailing P/E of 33.9x and net debt concerns misses the forward picture; forward P/E is 21.8x on 55% earnings growth, and debt funded an acquisition that delivered 710 bps gross margin expansion and repositioned EMR as software-tilted automation leader
→ vs conservative: Pricing in a recession with only 8% odds; current ratio of 0.90 is consistent with high deferred-revenue software models, not balance sheet deterioration
→ vs neutral: Waiting for clean breakout above $159.39 is paralysis not discipline; MACD already crossed bullish September 22, ATR compressing, and Bollinger Bands testing upper band at $159.83 indicate the move is already in motion
→ vs neutral: Treating 10-year at 2002 highs as death sentence for cyclicals ignores that industrial automation thrives in soft landing regimes; companies are modernizing, not cutting capex
| 0.81 |
| bullish |
| ATR (14) | 3.67 | neutral |
Support: 148.3 · 152.01 · 145.83 · 144.19 · 143.58 | Resistance: 159.39 · 159.83 · 163 · 164.31
EMR is in a confirmed long-term uptrend (price 8% above 200 SMA at 143.58, which is rising), with improving short-term momentum following a bullish MACD crossover and neutral RSI at 53.35 suggesting room to extend. Price has reclaimed the 50 SMA and 10 EMA after a September washout that bottomed at 145.83, currently trading between Bollinger mid-band (152.01) and upper-band (159.83). ATR has compressed to 3.67 (2.4% of price) from August's 5.14 peak, enabling tighter stop placement near 147.76 (2x ATR below close). The analyst rates the stock as HOLD, waiting for either a breakout above 159.39 on rising volume with MACD histogram > +1.0 and RSI > 60, or a pullback entry to the 152-154 zone; key risk is a daily close below 148.30 that would re-expose the 144.19 lower band and 200 SMA.
Market Cap
$88.5 B
Share Price
~$158.55
52-Week Range
$122.64 – $166.35
Beta
1.23
Dividend Yield
1.43%
P/E (TTM)
33.9x
Forward P/E
21.8x
PEG Ratio
1.79
Price / Book
4.34x
EV/EBITDA
~17x
Revenue (FY2025)
$18,016 M
Gross Margin
52.8%
Operating Margin
19.6%
Operating Margin (TTM)
26.9%
EBITDA (FY2025)
$4,839 M
EBITDA Margin (TTM)
~32.5%
Net Income (continuing, FY2025)
$2,238 M
Diluted EPS (FY2025)
$4.04
Diluted EPS (TTM)
$4.68
Forward EPS
$7.27
Net Profit Margin
13.8%
ROE
12.8%
ROA
6.9%
Revenue 3-yr CAGR
~9.3%
Forward EPS Growth
~55%
Cash & Equivalents
$1,544 M
Total Assets
$41,964 M
Goodwill & Intangibles
$27,651 M
Total Debt
$13,759 M
Net Debt
$11,572 M
Net Debt / EBITDA
~1.9x
Current Ratio
0.90
Debt-to-Equity
0.68
Operating Cash Flow (FY2025)
$3,098 M
Free Cash Flow (FY2025)
$2,667 M
FCF Margin
14.8%
CapEx
$431 M
Dividends Paid
$1,192 M
Buybacks
$1,167 M
50-Day MA
$153.93
200-Day MA
$144.39
Share Count
562.8 M
Strengths
Concerns
Emerson Electric is a diversified industrial-software and automation company with strong operating margins of 26.9% (TTM) and robust FCF generation of $2.67B in FY2025. The transformative National Instruments acquisition (~$8.3B, closed Oct 2023) has repositioned the company toward higher-margin software content, expanding gross margins by ~710 bps since FY2022. The stock trades at a premium trailing P/E of 33.9x but the forward P/E of 21.8x and consensus FY2026 EPS of $7.27 (~55% growth) provide a reasonable entry point on pullbacks. Balance sheet leverage has stepped up materially with net debt nearly tripling to $11.6B, though the 1.9x Net Debt/EBITDA remains manageable.
Macro: The macro backdrop is mixed-to-cautious for EMR. Long Treasury yields have reached levels not seen since 2002 and Fed officials are unanimously pushing back on rate-cut hopes, creating meaningful headwinds for a cyclical, long-duration industrial. The 10Y posted its biggest monthly gain since 2022, confirming a sustained repricing rather than a spike. However, markets are pricing a very low probability of recession (8% per Polymarket), supporting a soft-landing/no-landing consensus. The Smart Manufacturing category is forecast to double from $233B to $479B by 2029, providing a secular automation tailwind. EMR is currently a macro-and-thematic trade absent company-specific news, with the dominant near-term driver being bond market direction and its correlation with capital goods order patterns.